| 证券代码：603939 | 证券简称：益丰药房 公告编号：2025-070 | | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | 益丰大药房连锁股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2025 年 8 月 25 日 14 点 30 分 召开地点：湖南省长沙市金洲大道 68 号益丰医药物流园三楼会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 8 月 25 日 至2025 年 8 月 25 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互 (七) 涉及公开征集股东投票权 无。 二、 会议审议事项 本次股东会审议议案及投票股东类型 股东会召开日期：2025年8月2 ...

益丰大药房连锁股份有限公司 第五届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-066 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 表决结果：3 票同意，0 票反对，0 票弃权。 一、 监事会会议召开情况 益丰大药房连锁股份有限公司（以下简称"公司"）于 2025 年 7 月 25 日以 电子邮件方式发出第五届监事会第十三次会议通知，会议于 2025 年 7 月 30 日在 湖南省长沙市金洲大道 68 号益丰医药物流园五楼会议室召开，应参加表决的监 事 3 人，实际参加表决的监事 3 人，会议以现场方式召开，本次会议的召集、召 开和表决程序符合有关法律、法规和《公司章程》的规定，会议形成的决议合法 有效。 二、 监事会会议审议情况 本次会议由监事会主席陈斌先生召集并主持，采用记名投票方式，通过了如 下议案： （1）《关于取消监事会并修订<公司 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Views - The innovation environment is continuously improving, leading to an optimistic outlook on innovation premiums. In the first half of 2025, global pharmaceutical transactions reached 456, a 32% year-on-year increase, with total upfront payments soaring to $11.8 billion, a 136% increase. The total transaction value hit $130.4 billion, up 58% year-on-year, with Chinese companies contributing nearly 50% of the total value and over 30% of the transaction count [3] - The CXO sector is expected to gradually recover following a supply-side cleansing post-COVID-19, with a significant increase in License-out transactions and total transaction amounts surpassing previous years [4] - The TCE technology is being continuously iterated and updated, with promising clinical data emerging for TCE-based therapies, indicating a strong market potential [5] - The trend towards more effective and scientific weight loss solutions is evident, with GLP-1 drugs generating over $50 billion in global sales, driving capital interest in the sector [6] - There is a growing focus on autoimmune diseases, with significant clinical data supporting new treatments and collaborations in the field [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.21 percentage points in the last week, with a weekly increase of 1.90% [18] - Over the past month, the industry outperformed the CSI 300 index by 6.73 percentage points, with a monthly increase of 10.95% [21][24] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical and biotechnology industry index currently has a PE (TTM) of 37.98, above the 5-year historical average of 32.08 [41] 3. Recent Research Achievements - The report highlights various recent research findings, including the positive outlook for the blood products industry and the acceleration of the inhalation drug sector due to policy support [45] 4. Recent Industry Policies and News - The National Healthcare Security Administration has implemented measures to support the high-quality development of innovative drugs, enhancing the support for R&D and clinical applications [46] - Recent news includes significant approvals and collaborations in the pharmaceutical sector, indicating a vibrant market environment [48][49] 5. Key Company Recommendations - The report recommends specific companies based on their potential to benefit from the improving innovation environment and market trends, including CXO firms and those involved in TCE technology [8]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-064 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于使用闲置募集资金委托理财到期赎回 并继续委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次赎回产品名称：利多多公司稳利 25JG6297 期(三层看涨)人民币对公结 构性存款（7,000.00 万），2025 年第 444 期公司客户结构性存款（2,100.00 万）， 2025 年第 445 期公司客户结构性存款（2,100.00 万）。 赎回金额：11,200.00 万元 本次继续委托理财金额：10,600.00 万元 已履行的审议程序：经公司第五届董事会第十五次会议审议通过，同意在 确保不变相改变募集资金用途与不影响募集资金投资项目正常运行的情况下，使 用最高额度不超过 30,000.00 万元募集资金进行委托理财，用于购买安全性高、 流动性好的理财产品，自董事会审 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Summary of Key Points from the Conference Call Industry Overview - **Industry Focus**: The conference call primarily discusses the healthcare sector in China, particularly the medical technology (Medtech), in vitro diagnostics (IVD), retail pharmacies, hospitals, vaccines, and insulin markets [1][2]. Core Insights and Arguments Medtech - **Key Areas of Focus**: 1. Progress of capital equipment value-based procurement (VBP) and the trade-in policy [1] 2. Channel destocking trends [1] 3. Import substitution trends post-VBP, including intraocular lenses (IOLs) and IVD [1] - **VBP Impact**: The June bidding value data showed a year-on-year growth rate of 49%, but a month-on-month decline of 3%, indicating lower unit prices due to VBP [10]. IVD Market - **Weak Demand**: The IVD sector continues to face challenges, with a projected 20% year-on-year decline in the CLIA reagent market size for 2025 [19]. - **AmoyDx Performance**: AmoyDx is expected to grow against the trend due to its strong presence in compliant in-hospital sales channels, benefiting from the anti-corruption campaign [21]. Insulin Market - **Domestic Substitution**: The insulin industry has seen significant growth, particularly for insulin analogs from companies like Gan & Lee and THDB, which reported rapid revenue growth in 1Q25 [22]. Retail Pharmacies - **Market Pressure**: Retail pharmacies are under pressure due to strict reimbursement policies and weak consumer spending. However, there is a potential market-clearing trend expected by year-end [31]. Hospitals - **New Product Feedback**: Hospitals are seeing new product introductions, such as the new version of SMILE surgery and new PIOL products, which are expected to drive consumption recovery [1]. Vaccine Market - **Anti-Corruption Campaign**: The ongoing anti-corruption campaign within the CDC system is impacting vaccine demand and distribution channels [1]. Financial Performance and Estimates Earnings Revisions - **Mindray**: Annual earnings estimates revised down by 2.1% to 5.0% for 2025E-27E due to industry headwinds in medical equipment and IVD [2][37]. - **United Imaging**: Revenue and earnings forecasts adjusted down to reflect lower-than-expected bidding data [39]. - **SNIBE**: Earnings estimates revised down by 1.4% to 7.1% for 2025E-27E due to policy headwinds in the IVD sector [40]. Revenue Growth Expectations - **High Growth Companies**: THDB and Gan & Lee are expected to achieve the highest revenue growth due to a low base from VBP renewal in 2Q24 [6]. - **Mindray's Decline**: Mindray's China business is expected to decline by 26% year-on-year in 2Q25 due to IVD weakness [9]. Other Important Insights - **Trade-in Policy Concerns**: The trade-in stimulus fund is expected to run out, leading to a decline in applications and a reduced stimulus effect in the second half of 2025 [10]. - **Market Dynamics**: The healthcare market is experiencing a shift with increasing government support for procurement and a focus on innovative products [47][48]. Conclusion - The healthcare sector in China is facing various challenges, including policy headwinds, weak demand in certain segments, and the impact of ongoing reforms. However, there are also opportunities for growth, particularly in innovative products and domestic substitution trends. Companies like AmoyDx, Gan & Lee, and THDB are positioned to benefit from these trends, while others like Mindray and SNIBE are facing headwinds that may impact their performance in the near term.

Group 1 - The core index of the China Securities Index for Food and Major Consumer Goods Retail has shown a recent upward trend, with a 4.43% increase over the past month, a 0.49% increase over the past three months, and a year-to-date decline of 3.88% [1] - The index is composed of listed companies in the food and drug retail sector, reflecting the overall performance of these companies, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the index include Yonghui Supermarket (6.49%), Digital China (6.34%), Shanghai Pharmaceuticals (4.65%), Yifeng Pharmacy (4.23%), and others [1] Group 2 - The market share of the index's holdings is divided between the Shanghai Stock Exchange (53.16%) and the Shenzhen Stock Exchange (46.84%) [1] - In terms of industry composition, the index shows that pharmaceutical commerce accounts for 44.64%, supermarkets and convenience stores for 20.60%, specialty retail for 20.32%, and department stores for 14.44% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2]

Summary of Conference Call Notes Industry or Company Involved - The discussion primarily revolves around the pharmaceutical industry, particularly focusing on the implications of U.S. drug pricing policies and U.S.-China trade negotiations on Chinese pharmaceutical companies and their market opportunities. Core Points and Arguments 1. **Positive Impact of U.S.-China Negotiations on Pharmaceuticals** The recent U.S.-China negotiations are viewed as a significant positive for the pharmaceutical sector, alleviating previous concerns regarding trade impacts on drug pricing and exports of innovative drugs and raw materials [1] 2. **U.S. Drug Pricing Policy Changes** Trump's announcement of an executive order to reduce prescription drug prices by 30% to 80% is highlighted. The U.S. drug pricing system, characterized by high list prices, is under scrutiny, with the potential for significant price reductions impacting the market [2][3] 3. **Global Drug Pricing Context** U.S. drug prices are noted to be among the highest globally, particularly for innovative drugs, which are approximately 300% higher than prices in countries like Japan and Germany. This pricing structure encourages innovation but also raises concerns about affordability [3] 4. **Encouragement of Competition** The U.S. policy aims to accelerate competition among high-priced drugs, encouraging the entry of biosimilars and generic drugs, which could benefit Chinese pharmaceutical companies that can offer lower-cost alternatives [4][6] 5. **Opportunities for Chinese Pharmaceutical Companies** The reduction in U.S. drug prices is expected to create opportunities for Chinese companies, particularly in the fast-follow and biosimilar segments, as they can provide high-quality, cost-effective alternatives [6][8] 6. **Long-term Trends Favoring Chinese Innovation** The inefficiencies in innovation among multinational pharmaceutical companies may lead to increased reliance on Chinese innovation and manufacturing capabilities, especially if U.S. companies face cost pressures [7][8] 7. **Market Dynamics and Export Opportunities** The easing of trade tensions is anticipated to enhance the macroeconomic environment in China, leading to improved domestic demand and potential export opportunities for medical devices and raw materials [10][9] 8. **Impact of Drug Price Reductions on Market Dynamics** The anticipated drug price reductions in the U.S. are not expected to significantly diminish the addressable market for Chinese companies, as their market share in the U.S. remains relatively small [11][12] 9. **Long-term Supply Chain Considerations** U.S. concerns regarding supply chain security may lead to a push for domestic manufacturing, which could have long-term implications for Chinese companies seeking to penetrate the U.S. market [14][15] 10. **Investment Recommendations** The call suggests focusing on three categories of companies: innovative leaders, those with strong business development (BD) expectations, and upstream suppliers with global advantages, as the market enters a new growth cycle [16][18] Other Important but Possibly Overlooked Content 1. **Sector-Specific Insights** The discussion includes insights into specific companies and their competitive advantages, such as the potential for certain drugs to achieve significant market penetration despite pricing pressures [31][33] 2. **Emerging Trends in Medical Devices** The call also touches on the medical device sector, emphasizing the importance of high-end equipment and the potential for growth in home healthcare products, which may offer higher profit margins compared to domestic markets [25][26] 3. **Long-term Growth Projections** There is an optimistic outlook for the pharmaceutical sector, with expectations of a gradual recovery in demand and performance improvements in the coming years, driven by policy support and market dynamics [29][40] 4. **Focus on Innovation and R&D** The emphasis on innovation and the need for companies to adapt to changing market conditions is reiterated, highlighting the importance of R&D in maintaining competitive advantages [19][20] 5. **Market Sentiment and Future Outlook** The overall sentiment is cautiously optimistic, with a belief that the current market conditions present opportunities for growth and investment in the pharmaceutical and medical device sectors [46][47]

Market Overview - The Shanghai Composite Index is at 3500.42 points, slightly down by 0.13%, with a total trading volume of 674.96 billion yuan [1] - As of now, 50 A-shares have surpassed their annual line, indicating a positive market sentiment [1] Notable Stocks - The stocks with the highest deviation rates above the annual line include: - Furui Co., Ltd. (300049) with a deviation rate of 5.83% and a daily increase of 7.83% [1] - Haide Co., Ltd. (000567) with a deviation rate of 4.84% and a daily increase of 7.77% [1] - Tianye Co., Ltd. (832023) with a deviation rate of 3.71% and a daily increase of 6.35% [1] - Other stocks that have just crossed the annual line with smaller deviation rates include: - Wansheng Co., Ltd. (002739) with a deviation rate of 2.70% and a daily increase of 3.02% [1] - ST Guandian (688287) with a deviation rate of 2.14% and a daily increase of 2.67% [1] Trading Activity - The trading turnover rate for notable stocks varies, with Furui Co., Ltd. at 4.06% and Haide Co., Ltd. at 2.59% [1] - The latest prices for these stocks are as follows: - Furui Co., Ltd. at 39.40 yuan [1] - Haide Co., Ltd. at 6.52 yuan [1] - Tianye Co., Ltd. at 4.69 yuan [1]

Core Viewpoint - The chain pharmacy industry in China is facing significant challenges, including declining profits, difficulties in online transformation, and a lack of investor confidence, leading to a period of deep adjustment and potential consolidation [1][8][16]. Group 1: Industry Performance - In 2024, only Yifeng Pharmacy among the six major listed chain pharmacy brands achieved profit growth, while the other five experienced varying degrees of profit decline [1][5]. - The revenue growth of the six major chains did not exceed 10% in 2024, with the highest growth at 8.01%, a stark contrast to previous years where growth often exceeded 10% [5][6]. - Yifeng Pharmacy was the only company to report profit growth, while others, including Shuyupingmin, faced their first losses since 2019 [6][7]. Group 2: Market Dynamics - The number of offline pharmacies in China grew from 520,000 in 2019 to 700,000 in 2024, with major chains aggressively expanding through various methods [2]. - The expectation of prescription outflow has not materialized, with prescriptions returning to grassroots medical institutions instead of flowing to retail pharmacies [3][4]. - The introduction of stricter regulations, such as comprehensive inspections of pharmacies and mandatory traceability codes, has increased compliance costs for pharmacies [4]. Group 3: Investor Sentiment - There have been multiple instances of major shareholders in chain pharmacies, such as Yifeng and Laobaixing, reducing their stakes, raising concerns about the industry's future [7]. - Several chain pharmacies are reportedly seeking to sell their businesses, but a lack of interested buyers indicates a significant loss of confidence in the industry [1][6]. Group 4: Online Transition - The online pharmacy market is growing, with online sales reaching 329.2 billion yuan in 2024, while physical pharmacy sales declined for the first time [10]. - Major online pharmacy players like JD Health and Alibaba Health reported strong revenue growth, contrasting with the struggles of traditional pharmacies [10][11]. - Chain pharmacies are increasingly investing in online channels, with significant growth in their O2O (Online to Offline) sales, although they face challenges in competing with larger platforms [11][12]. Group 5: Strategic Shifts - Chain pharmacies are exploring non-pharmaceutical business models, with companies like Yixin Tang and Laobaixing diversifying their product offerings to include health and personal care items [14][15]. - The shift towards a more diversified product range aims to reduce reliance on prescription sales and adapt to changing consumer preferences [14][16]. - The industry is undergoing a transformation phase, necessitating a reevaluation of value propositions in light of declining prescription flows and increased competition from e-commerce [16][17].